Ariana Pelosci

A phase 2/3 trial found that patients with low-grade serous ovarian cancer treated with trametinib had improved survival over the standard of care.

Patients with metastatic castration-resistant prostate cancer treated with apalutamide and prednisone experienced a better radiographic progression-free survival vs an active and established comparator regimen.

The phase 2 PERMEATE trial yielded positive results in the combination of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases.

In patients with completely resected non–small cell lung cancer with mediastinal N2 involvement, postoperative radiotherapy was not associated with an increase in disease-free survival.

Treatment with armodafinil did not result in a significant difference in cancer-related fatigue between treatment arms for patients with high-grade glioma.

Consolidation therapy with bortezomib, lenalidomide, and dexamethasone plus lenalidomide maintenance improved progression-free survival in patients with newly diagnosed multiple myeloma.

Patients with HER2-positive breast cancer who were treated with trastuzumab deruxtecan experienced favorable activity and reduction or loss of HER2 expression.

According to a study conducted at a single cancer center in Southern Maryland, patients who survived breast or prostate cancer were less likely to receive a colorectal cancer screening.

Experts explored existing data to create a universal definition of integrative oncology, in tandem with feedback from Society of Integrative Oncology, to better explains what the term means.

Patients with metastatic cutaneous squamous cell carcinoma who were treated with cosibelimab experienced a positive objective response rate.

BNT200 is a device designed to treat anxiety and depressive symptoms in adults with acute myeloid leukemia.

Jun Gong, MD, hosted a Twitter takeover during the 2022 Gastrointestinal Cancers Symposium where he discussed breaking presentations in a #CNRealtimeReport.

Fosnetupitant demonstrated non-inferiority and a favorable safety profile vs fosaprepitant for chemotherapy-induced nausea and vomiting.

It is important to tap into interventions that can mitigate a fear of cancer recurrence in the partners of multiple myeloma survivors in addition to improving family hardiness and social support in order to aid in patients' psychological adjustment and wellbeing.

The FDA has given a fast track designation to gedatolisib as a treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Tebentafusp has been approved by the FDA based on results of the phase 3 IMCgp100-202 trial for patients harboring HLA-A*02:01 with metastatic uveal melanoma.

Patients with pretreated gastrointestinal stromal tumors who were treated with ripretinib did not reach the primary end point of progression-free survival superiority vs sunitinib in the phase 3 INTRIGUE study.

Patients with stage IV non–small cell lung cancer treated with sugemalimab plus chemotherapy experienced a prolonged overall survival benefit compared with those who received placebo and chemotherapy.

Patients with chronic lymphocytic leukemia treated with fixed duration venetoclax/rituximab may experience prolonged disease control vs bendamustine/rituximab.

The observational GALAXY study found that use of a ctDNA assay could help determine which patients with colorectal cancer stand to benefit the most by receipt of adjuvant chemotherapy.

Patients with biliary tract cancer who were given the adjuvant oral fluoropyrimidine derivative S-1 had better overall survival compared with surgery alone.

Patients undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma experienced a better overall survival when treated with adjuvant chemotherapy.

Women diagnosed with ovarian cancer were reported to have longer waiting times for treatment vs other cancer types with the exception of kidney cancer.

Patients with breast cancer who were treated at a community-based oncology practice that used routine depression screening were more likely to a receive referral for behavioral care vs those in an education-only cohort.

Use of a multimedia education platform appeared to compliment traditional education methods and provide complementary information on treatment and recovery for those with head and neck cancer.

Patients diagnosed with early-stage ovarian cancer who are treated with novel targeted therapies may experience better overall survival and less financial toxicity compared with those who have late-stage disease.

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A pooled analysis indicated that patients who were 80 years or older had efficacious responses to targeted therapies for chronic lymphocytic leukemia regardless of coexisting conditions and organ dysfunction.

Patients with mantle cell lymphoma treated in academic facilities appeared to have a longer overall survival compared those treated at with non-academic centers.

Suicide risk increased among patients who had a lower-income and lived in rural counties following a cancer diagnosis.